Navigation Links
MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
Date:9/10/2009

LEVADEX Analysis Shows Potential to Treat a Broad Spectrum of Migraine ***UPDATED SATELLITE COORDINATES***

Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient response and side effects such as heightened blood pressure.

MAP Pharmaceuticals, Inc. will present analysis of data from the efficacy portion of the first Phase 3 trial of LEVADEX(TM) at the 14th Congress of the International Headache Society. Data from this Phase 3 trial show the potential of LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine, including migraine subpopulations that are often resistant to current therapies, migraine with moderate and severe pain, migraine with nausea and vomiting, and migraine with and without aura. LEVADEX is an orally inhaled migraine therapy that patients administer themselves using the company's proprietary TEMPO(R) inhaler.

    SATELLITE FEED:
    Thursday, September 10th, 2009
    2:00 PM - 2:15 PM ET
    Galaxy 19
    C-Band
    Transponder 10
    Downlink Freq. 3900 Horizontal

NEWS: New Data Presented at the International Headache Society's Annual Congress Suggests New, Investigational Migraine Treatment Could Help Provide Relief for 30 Million Sufferers in the U.S.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/40023/consumer.html


    SOUNDBITES:
    * Dr. Stephen Silberstein, Director of the Headache Center, Jefferson
      University Hospitals
    * Migraine patient

    B-ROLL INCLUDES:
    * Dr/Patient footage
    * MAP corporate headquarters - exteriors and lab footage
    * manufacturing footage
    * product shots

VIDEO PROVIDED BY: MAP Pharmaceuticals, Inc.

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
4. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
5. Medigus and Tower Semiconductor Announce Worlds Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
6. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
10. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
11. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):